HM74 Polyclonal Antibody

    • Catalog No.:YT2182
    • Applications:WB;IF;ELISA
    • Reactivity:Human;Mouse;Rat
      • Target:
      • HM74
      • Fields:
      • >>cAMP signaling pathway
      • Gene Name:
      • HCAR2/HCAR3
      • Protein Name:
      • HM74A/HM74B
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human GPR109. AA range:285-334
      • Specificity:
      • HM74 Polyclonal Antibody detects endogenous levels of HM74 protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. IF 1:200 - 1:1000. ELISA: 1:10000. Not yet tested in other applications.
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • HCAR3;GPR109B;HCA3;HM74B;NIACR2;Hydroxycarboxylic acid receptor 3;G-protein coupled receptor 109B;G-protein coupled receptor HM74;G-protein coupled receptor HM74B;Niacin receptor 2;Nicotinic acid receptor 2;HCAR2;GPR109A;HCA2;Hydroxycarboxylic acid receptor 2;
      • Observed Band(KD):
      • 45kD
      • Background:
      • developmental stage:Expression in neutrophils occurs in the late terminal differentiation phase.,function:Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.,miscellaneous:The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.,similarity:Belongs to the G-protein coupled receptor 1 family.,tissue specificity:Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.,
      • Function:
      • developmental stage:Expression in neutrophils occurs in the late terminal differentiation phase.,function:Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.,miscellaneous:The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-meth
      • Subcellular Location:
      • Cell membrane; Multi-pass membrane protein.
      • Expression:
      • Expression largely restricted to adipose tissue and spleen.
      • Products Images
      • Immunofluorescence analysis of MCF7 cells, using GPR109 Antibody. The picture on the right is blocked with the synthesized peptide.
      • Western blot analysis of lysates from RAW264.7 cells, using GPR109 Antibody. The lane on the right is blocked with the synthesized peptide.
      • Western blot analysis of the lysates from HepG2 cells using GPR109 antibody.